For providers

Transform the future of cancer screening with the Cancerguard™ test

One simple blood draw can help you detect cancer earlier and impact more lives.1
A doctor and patient walking in a sunny lobby and discussing test results.
For adults 50-84, with no cancer in the last 3 years1
Helps detect cancer types behind at least 80% of diagnoses2
Helps detect aggressive cancers, including 6 of the most deadly*,†,2
$689, HSA/FSA eligible‡
A doctor and patient walking in a sunny lobby and discussing test results.

~70% of annual cancer cases and deaths have no recommended screening3

With ~600,000 deaths in the US every year, cancer is the 2nd deadliest disease4

Recommended screening only catches 1 in 7 cancers§,5

Only 4 types of cancer have recommended screening options3

The Cancerguard test dramatically expands your screening power

The Cancerguard test

Helps find the deadliest cancers

Cancerguard showed a 68% sensitivity for the most deadly cancers with the lowest 5-year survival rates like pancreatic, lung, liver, esophageal, stomach, and ovarian cancers. It can offer clear, life-changing insights earlier, when treatment can make the biggest difference.2
Helps find cancer types behind at least 80% of diagnoses2

Cancerguard screens for cancer types responsible for the majority of annual cancer diagnoses in the U.S. including the ones that are hardest to find.

With Cancerguard, you can expand your screening capabilities to enable more comprehensive proactive care.

Detected more than 1 in 3 early stage cancers2

Catching cancer earlier can change everything. The Cancerguard test found 1 in 3 early-stage cancers in a study.2

You can help your patients move forward with confidence--and stay one step ahead of even the most aggressive cancers.

97.4% specificity may limit false positives2

With high specificity, the Cancerguard test delivers actionable results.

Low false positive rates, which minimize unnecessary imaging and follow up, mean you can do more for your patients.

Designed for precision

Multiple biomarker classes. Actionable results.

The only test of its kind to combine DNA methylation and protein biomarkers2

  • Analyzing multiple biological signals casts a wider net for detecting cancer in its early stages.
  • Our multi-biomarker class approach boosts detection of 6 of the deadliest cancer* organ types with the shortest 5-year survival rate.
  • The Cancerguard test is designed to detect more than 50 cancer types and subtypes.||

Designed to minimize unnecessary follow-ups

Cancerguard was designed to streamline the diagnostic workflow after a patient receives a positive result.
A doctor looking at patient results on a tablet.

Expert-designed imaging workflow

Developed by radiologists and health system experts to ease implementation

Less guesswork. Greater efficiency.

An imaging-based diagnostic workflow designed to help you provide consistent, reliable follow-up care for patients

Showed a ~30% reduction in diagnostic burden

Fewer procedures vs. molecular methods on modeling outcomes6
Imaging resolution workflow is based on published expert clinician opinion and results from an exploratory, prospective, interventional modeling study. It is not a replacement for clinical standard of care. There are no established guidelines for imaging following a positive Cancerguard test result. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients.

Trusted guidance to ease patient anxiety

When patients test positive, we're here to help them. Our Positive Results Services provide patients with hands-on guidance for their next steps.
Two women sitting on a couch smiling and talking.
Patient Care Navigation

Our Care Navigators can act as a patient’s personal guide after a positive test result and cover things like:

  • Finding locations for follow-up imaging and testing
  • Providing eligibility details for our Patient Imaging Reimbursement Program
  • Help assess and reduce barriers to getting follow-up care
A close up of an imaging scan.
Imaging Reimbursement Program

Coverage of follow-up imaging after a positive result varies based on insurance plans and a patient’s unique situation. If a patient has a positive test result, our imaging reimbursement program can help reduce the financial impact for eligible patients, so they can stay focused on their health. Patients must apply and eligibility depends on program qualifications and is not guaranteed.

The Imaging Reimbursement program will not reimburse any covered imaging costs, including copay, coinsurance and/or deductible amounts determined by insurance.

Results designed for clarity.

Patients results are ready about 2 weeks after our lab receives their blood sample. Results are either positive or negative and can help you determine next steps. In rare cases, an invalid result can occur.6

Negative Result

A negative result means the test did not find signals of cancer.6
Your patient can continue with their recommended cancer screening schedule and standard of care.

Positive Result

A positive result means the test found a signal that may indicate the presence of cancer. It’s not a cancer diagnosis.7
Follow-up imaging and further evaluation are needed to locate and confirm a diagnosis, or determine that cancer is not present.8
*False negative and false positive results can occur. A false negative result means the test did not find signals of cancer, but a person does have cancer. A false positive result means the test found signals of cancer, but a person doesn’t have cancer.

Trust a leader in cancer diagnostics

With over two decades of experience helping millions navigate life-changing cancer diagnoses, Exact Sciences is redefining cancer screening with Multi-Cancer Early Detection (MCED) testing.9
Cologuard by Exact Sciences logo in black and white.
Oncotype DX Breast Recurrence Score logo in black and white.
Oncodetect molecular residual disease logo in black and white.
Riskguard Hereditary Cancer Test logo in black and white.
Two doctors smiling and laughing, walking down a set of concrete stairs.

Partnering with the brightest minds in cancer research

Exact Sciences has been leading the development of MCED testing in collaboration with the broader cancer community. We work with patient advocacy groups, forums, and researchers at premier institutions to help to shape the future of cancer detection.10

Get started today

The Cancerguard test is intended for people aged 50-84 with no cancer diagnosis in the last 3 years.1
A woman sitting on a couch, smiling and using a smartphone.

Three ways to use DNA to gain insight

Cancerguard is one of three distinct tests we offer that look for cancer in different ways. Here’s what sets them apart.
Cancerguard logo.
Screening

Multi-Cancer Early Detection (MCED) test

MCED tests like the Cancerguard test help detect hard-to-find cancers and in earlier stages when they are more treatable.
Riskguard hereditary cancer test logo.
Risk Detection

Hereditary Cancer Test
(HCT)

Tests like Riskguard® can help uncover hereditary cancer risk. It checks for genetic changes from your family line that can cause an increased risk for certain cancers.
Oncodetect molecular residual disease logo.
Monitoring

Molecular Residual Disease (MRD) test

MRD tests like Oncodetect™ are tumor-informed tests that can detect circulating tumor DNA in the blood during or after cancer treatment.

Have questions?

Call us at 844-870-8870.

Footnotes and references

  1. pancreatic, esophageal, liver, lung, stomach, ovarian
  2. American Cancer Society. Cancer Facts & Figures 2025. Cancer.org. Published 2025.
  3. $689 amount reflects self-pay price. FSA/HSA/HRA programs may be a resource you could use to pay as well.
  4. Limitations: Based on modeling data derived from numerous sources including self-reported surveys. Includes assumptions on detectability of certain cancer types. Does not include all cancer types or screening methods.
  5. Data on file. Cancerguard Cancer Subtype Analysis. Exact Sciences, Madison, WI; September 2025

  1. Exact Sciences. Exact Sciences Specimen Collection Guide Preparation Collection and Processing. Published 2024, Accessed June 13, 2025
  2. Data on file. Cancerguard Test development study. 2025. Bioinformatics, Exact Sciences, Madison, WI
  3. Data on file. Calculated cancers without USPSTF recommended screening tests. 2025.
  4. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer. J Clin. 2025;75(1):10‐45.
  5. NORC at the University of Chicago. Percent of Cancers Detected by Screening in the U.S. Published 2022. Accessed June 13, 2025
  6. Exact Sciences. Cancerguard™ Patient Support Guide. Published 2025 Accessed July 11, 2025.
  7. Exact Sciences. Patient Positive Result Supplement. Published 2025. Accessed July 11 2025
  8. Exact Sciences. Cancerguard™ Care Navigation Guide. Published 2025. Accessed July 23, 2025.
  9. Exact Sciences. Exact Sciences Company History. Published 2025. Accessed June 13, 2025
  10. Choudhry O, Kharge A, Rego S, et al. DETECT-A Participants with Pre-Malignant Conditions Diagnosed Consequent to an MCED Test.; 2024. Accessed June 13, 2025.

Important information about the Cancerguard test


Rx only. The Cancerguard™ test is indicated for use in adults ages 50-84 with no known cancer diagnosis in the last three years. It detects alterations in circulating tumor DNA and tumor-associated protein levels which are commonly associated with cancer. The test does not detect all cancers and is not a replacement for existing recommended cancer screening or diagnostic modalities for cancer. Current recommended screening for cancer should also be followed. The test is not indicated for screening of breast and prostate cancer and was not evaluated for the detection of pre-cancerous lesions. Due to the potential for follow-up imaging with IV contrast CT after a positive test result, careful consideration should be given before ordering the Cancerguard test for patients with a history of adverse reactions to iodine based IV contrast or for women who are, may be, or plan to become pregnant. Results should be interpreted in the context of a patient’s medical history, clinical signs, and symptoms. A negative result does not rule out the presence of cancer of any type. A positive Cancerguard™ test result means that the blood test identified a cancer signal that may indicate the presence of cancer. This result alone does not confirm the presence of cancer. Further clinical evaluation by a healthcare provider (which may include blood tests such as complete blood count and comprehensive metabolic panel) and follow-up imaging are needed to locate and confirm a diagnosis of cancer or determine that cancer is not present. While there are no established guidelines for imaging following a positive Cancerguard test result, there is a published follow-up workflow based on expert clinician opinion and results from an exploratory, prospective, interventional study [Kisiel et al Life (Basel) 2024 Jul 24; Lennon et al, Science, 2020]. The proposed workflow in the Kisiel et al publication includes an intravenous-contrast enhanced computed tomography (IV contrast CT of chest, abdomen/pelvis, and soft-tissue neck) and if necessary, positron emission tomography-computed tomography (18F FDG PET-CT) from the skull-base to mid-thigh. Alternative follow-up procedures (e.g. targeted imaging, endoscopic procedures, CT without IV- contrast) may be appropriate in the context of the patient’s medical history and clinical evaluation [Lennon et al, Science, 2020]. False positive and false negative test results can occur.

The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.